| Document Date: 2013-05-27 05:45:24
Open Document File Size: 198,33 KBShare Result on Facebook
City Brussels / / Company Bayer / Small-Medium Enterprises / European laboratories / / Continent North America / Europe / / Country Germany / Switzerland / Netherlands / Italy / Mexico / Chile / Poland / France / Japan / Austria / United Kingdom / Spain / Ireland / / Currency EUR / / Event FDA Phase / / Facility Building Europe / / IndustryTerm joint trans-national grant applications / magnetic resonance imaging / large pharmaceutical / pharmaceutical / food / disease-specific networks / increased biotechnology intellectual property rights / important applications / larger network / diagnostic tools / treatment of hypertension / technology platforms / research collaborative network / therapies of life-threatening diseases / therapeutics for these diseases / therapeutic applications / / MedicalCondition primary aldosteronism / namely pseudohypoaldosteronism / renal diseases / ocular / metabolic diseases / hyperaldosteronism / obesity / inflammatory cells / cardiac and renal ischemia reperfusion injury / chronic kidney diseases / cardiovascular diseases / proteinuria / hypertension / metabolic diseases / disease / adrenal tumours / kidney diseases / stroke / tumour / ocular diseases / diabetes / cardiovascular disease / ischaemic heart disease / tissue fibrosis / diabetes mellitus / heart failure / diseases / aldosterone/MR related diseases / high blood pressure / inflammation / cardiovascular and renal diseases / skin diseases / Moreover cardiovascular diseases / disorders / / Organization Action / Aldosterone Council / World Health Organisation / Management Committee / COST Committee of Senior officials / European Union / / Position researcher / General / / Product MR / / Technology biotechnology / drug screening / magnetic resonance imaging / genotype / drug development / /
SocialTag |
European Cooperation Brussels, 24 May 2013 in the field of Scientific and Technical Research